Physician profile
Jonathan Hassel
NPI 1871814202
$9,812.49
in general payments reported to CMS, 2019-2025
38 companies · $946 in 2025
The $946 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $853 · 2020: $773 · 2021: $1,707 · 2022: $2,165 · 2023: $1,811 · 2024: $1,556 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,181 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,180.91 |
| Education | $133.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,892.45 | 2019-2024 | Avvigo Guidance System, Synergy, Mamba |
| Novartis Pharmaceuticals Corporation | $1,192.19 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $821.93 | 2019-2024 | Farxiga, Andexxa |
| Edwards Lifesciences Corporation | $794.20 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Janssen Pharmaceuticals, INC | $662.62 | 2019-2024 | Xarelto |
| Medtronic, INC. | $614.26 | 2021-2023 | Onyx Frontier |
| Abiomed | $463.98 | 2019-2025 | Impella |
| Amgen INC. | $393.75 | 2019-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.18 | 2019-2025 | Jardiance |
| Asahi Intecc USA, INC. | $370.01 | 2023-2025 | Asahi Ptca Guide Wire, Asahi Peripheral Vascular Wires, Asahi Coronary Wires |
| Merck Sharp & Dohme LLC | $346.31 | 2021-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $278.63 | 2021-2025 | |
| Novo Nordisk INC | $220.97 | 2021-2023 | Ozempic |
| Pfizer INC. | $206.01 | 2019-2025 | |
| Amarin Pharma, INC. | $163.30 | 2020-2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Hassel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.